Table 2 Characteristics of interventional studies in this systematic review and meta-analysis
Authors | Country | Treatment | Dose of drugs | Study design | N/female (%) | Mean (age) | Durationa (year) | Length of follow-up (m) | Quality score | Outcome summary | BMI |
|---|---|---|---|---|---|---|---|---|---|---|---|
Ronda et al., 2015 [23] | USA | MTXc, ADAd, MTX | MTX: 3–5 mg ADA: 40 mg | One-arm study | 56 (NA) | 57.0 | 2.0 | 6 | 11 | CECb was not significantly altered after RA therapy | NA |
P.Liao et al., 2015 [24] | USA | MTX, INFe, MTX + INF | NAi | One-arm study | 80 (88.9) | 57.0 | 16.5 | 12 | 13 | CEC was improved in CEC after therapy | Baseline: 27 ± 5 |
O’Neill et al., 2016 [20] | UK | MTX + INF, MTX + PLAf | M + I: 5 mg/kg M + p: 2.5–25 mg/kg | Two-arm study | 18 (66.7) | 58.6 | 5.0 | 12 | 16 | CEC was not significantly altered after RA treatment | Treatment: 25 ± 5 placebo: 25 ± 1 |
Ormseth et al., 2016 [25] | USA | MTX, TCZg, ADAh | NA | Three-arm study | 59 (84.0) | 53.0 | 9.0 | 6 | 17 | CEC was not significantly altered after RA treatment | NA |
Ferraz-Amaro et al., 2019 [26] | UK | TCZ | 8 mg/kg | One-arm study | 24 (88) | 52.0 | 8.0 | 12 | 12 | CEC was significantly increased after RA treatment | Treatment: 29 ± 6 Baseline: 28 ± 5 |